Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

This study has been terminated.
(Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00317434
First received: April 20, 2006
Last updated: December 10, 2009
Last verified: December 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2007
  Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Publications: